Reviewer #3 (Public Review):
The authors examined mechanotransductive feedback dynamics that govern endothelial cell motility and vascular morphogenesis. They investigated endothelial cell morphology, migration speed, cell shape, cytoskeletal and focal adhesion maturation in human derived ECFC. To substantiate their in vitro data set, they imaged intersegmental vessel development in zebrafish embryos treated with various inhibitors of translation and acto-myosin remodelling . They conclude that the transcriptional regulators, YAP and TAZ, are activated by mechanical cues to transcriptionally limit cytoskeletal and focal adhesion maturation, forming a conserved mechanotransductive feedback loop that mediates endothelial cell motility. Mechanistically, YAP and TAZ induced transcriptional suppression of myosin II activity to maintain dynamic cytoskeletal equilibria. Such transcriptional feedback loop may be necessary for persistent endothelial cell migration and vascular morphogenesis. The authors addressed an interesting aspect of vascular development and I have some comments and suggestions that are listed below.
Comments:
The authors used ECFC - endothelial colony forming cells (circulating endothelial cells that activate in response to vascular injury).
Q: did the authors characterize these cells and made sure that they are truly endothelial cells - for example examine specific endothelial markers, arterial-venous identity markers & Notch signalling status, overall morphology etc prior to the start of the experiment. How were ECFC isolated from human individuals, are these "healthy" volunteers - any underlying CVD risk factors, cells from one patient or from pooled samples, what injury where these humans exposed to trigger the release of the ECPFs into the circulation, etc. The materials & methods on ECFC should be expanded.
The authors suggest that loss of YAP/TAZ phenocopies actinomycin-D inhibition - "both transcription inhibition and YAP/TAZ depletion impaired polarization, and induced robust ventral stress fiber formation and peripheral focal adhesion maturation". However, the cell size of actinomycin-D treated cells (Fig. 1B, top right panel), differs from the endothelial cell size upon siYAP/TAZ (Fig. 1E, top right panel) - and vinculin staining seems more pronounced in actinomyocin-D treated cells (B, bottom right) when compared to siYAP/TAZ group. Cell shape is defined by acto-myosin tension.
Q: besides Fraction of focal adhesion >1um; focal adhesion number did the authors measure additional parameters related to cytoskeleton remodelling / focal adhesions that can substantiate their statement on similarity between loss of YAP/TAZ and actinomycin-D treatment. Would it be possible to make a more specific genetic intervention (besides YAP/TAZ) interfering with the focal adhesion pathway as opposed to the broad spectrum inhibitor actinomyocin-D.<br /> Q: does the actinomycin-D treatment affect responsiveness to Vegf? induce apoptosis or reduce survival of the ECFC?<br /> Q: Which mechanism links ECM stiffness with endothelial surface area in the authors scenario. In zebrafish, activity of endothelial guanine exchange factor Trio specifically at endothelial cell junctions (Klems, Nat Comms, 2020) and endoglin in response to hemodynamic factors (Siekmann, Nat Cell Biol 2017) have been show to control EC shape/surface area - do these factors play a role in the scenario proposed by the authors.<br /> Q: the authors report that EC migrate faster on stiff substrate, and concomitantly these cells have a larger surface area. What is the physiological rationale behind these observations. Did the authors observe such behaviors in their zebrafish ISV model? How do these observation integrate with the tip - stalk cell shuffling model (Jakobsson&Gerhardt, Nat Cell Biol, 2011) and Notch activity in developing ISVs.
The authors examined the formation of arterial intersegmental vessels in the trunk of developing zebrafish embryos in vivo. They used a variety of pharmacological inhibitors of transcription and acto-myosin remodelling and linked the observed morphological changes in ISV morphogenesis with changes in endothelial cell motility.<br /> Q: reduced formation and dorsal extension of ISVs may have several reasons, including reduced EC migration and proliferation. The Tg(fli1a:EGFP) reporter however is not the most suitable line to monitor migration of individual endothelial cells. Can the authors repeat the experiments in Tg(fli1a:nEGFP); Tg(kdrl:HRAS-mCherry) double transgenics to visualise movement-migration of the individual endothelial cells and EC proliferation events, in the different treatment regimes.<br /> ISV formation is furthermore affected by Notch signalling status and a series of (repulsive) guidance cues.<br /> Q: Does de novo blockade of gene expression with Actinomycin D affect Notch signalling status, expression of PlexinD - sFlt1, netrin1 or arterial-venous identify genes.
Remark: the authors may want to consider using the Tg(fli1:LIFEACT-GFP) reporter for in vivo imaging of actin remodelling events.
Remark: the authors report "As with broad transcription inhibition, in situ depletion of YAP and TAZ by RNAi arrested cell motility, illustrated here by live-migration sparklines over 10 hours: siControl: , siYAP/TAZ: (25 μm scale-bar: -)". Can the authors make a separate figure panel for this, how many cells were measured?<br /> Remark: in the wash-out experiments, exposure to the inhibitors is not the same in the different scenarios - could it be that the longer exposure time induces "toxic" side effect that cannot be "washed out" when compared to the short treatment regimes?